PRESS RELEASE published on 06/05/2025 at 14:30, 5 months 29 days ago Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome Telomir-1 treatment shows promising results in reversing aging hallmarks in a rare genetic disorder. Findings include restored gene control, extended telomere length, muscle and weight recovery, reduced oxidative stress, and 100% survival Preclinical Data Genetic Disorder Telomir-1 Age-Reversal Telomere Length
BRIEF published on 06/02/2025 at 14:35, 6 months 2 days ago Telomir Pharmaceuticals to Advance Age-Reversal Research at BIO 2025 Rare Diseases IND Submission Telomir-1 Age-Reversal Preclinical Success
BRIEF published on 06/02/2025 at 14:35, 6 months 2 days ago Telomir Pharmaceuticals fera progresser la recherche sur l'inversion du vieillissement au BIO 2025 Maladies Rares Telomir-1 Inversion Du Vieillissement Soumission IND Succès Préclinique
PRESS RELEASE published on 06/02/2025 at 14:30, 6 months 2 days ago Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform Telomir Pharmaceuticals, Inc. to meet prospective partners at BIO International Convention 2025 to accelerate IND submission for Telomir-1, preparing for human dosing in 2026 BIO International Convention IND Submission Telomir-1 Telomir Pharmaceuticals Human Dosing
BRIEF published on 05/29/2025 at 14:35, 6 months 6 days ago Telomir-1 Shows Promise in Restoring Vision in AMD Animal Model Telomir-1 Retina Regeneration AMD Model Zebrafish Study Vision Restoration
BRIEF published on 05/29/2025 at 14:35, 6 months 6 days ago Telomir-1 s'avère prometteur pour restaurer la vision dans un modèle animal de DMLA Telomir-1 Régénération De La Rétine Modèle AMD Étude Sur Le Poisson Zèbre Restauration De La Vision
PRESS RELEASE published on 05/29/2025 at 14:30, 6 months 6 days ago Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints Telomir Pharmaceuticals reports positive preclinical results for oral drug Telomir-1 in age-related macular degeneration (AMD) model, showing vision restoration, retinal regeneration, and reduced oxidative stress Preclinical Results Telomir-1 Telomir Pharmaceuticals Age-related Macular Degeneration Vision Restoration
BRIEF published on 05/15/2025 at 14:05, 6 months 20 days ago Telomir Pharmaceuticals Introduces Telomir-Ag2, Targeting Drug-Resistant Infections Antimicrobial Resistance Healthcare Market Telomir Pharmaceuticals Silver(II) Stabilization Drug-resistant Pathogens
BRIEF published on 05/15/2025 at 14:05, 6 months 20 days ago Telomir Pharmaceuticals présente Telomir-Ag2, un médicament ciblant les infections résistantes aux médicaments Résistance Aux Antimicrobiens Telomir Pharmaceuticals Stabilisation À L'argent (II) Agents Pathogènes Résistants Aux Médicaments Marché De La Santé
PRESS RELEASE published on 05/15/2025 at 14:00, 6 months 20 days ago Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity Telomir Pharmaceuticals, Inc. announces Telomir-Ag2, a novel drug candidate addressing antimicrobial resistance with broad-spectrum activity, particularly against drug-resistant pathogens Antimicrobial Resistance Drug Candidate Telomir Pharmaceuticals Inc. Telomir-Ag2 Silver(II) Complex
Published on 12/05/2025 at 02:35, 10 hours 38 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 12 hours 13 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 8 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 13 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 13:00, 13 minutes ago Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 13 minutes ago Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 8 minutes ago Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 13 minutes ago CGTN:Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 1 hour 13 minutes ago Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million
Published on 12/05/2025 at 08:45, 4 hours 28 minutes ago Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 4 hours 28 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 4 hours 31 minutes ago ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 18 hours 58 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 19 hours 13 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025